For patients with early-stage hormone receptor-positive (HR +) breast cancer (BC), 5 to 10 years of adjuvant hormone therapy can significantly slow down regional and remote recurrence and increase overall survival (OS) [1]. Here, NR4A1 is linked to breast carcinoma.